ANALYSIS OF THE DYNAMICS OF PROVIDING PREVENTIVE MEDICINES TO PATIENTS WITH MALIGNANT NOMINATIONSOF THE PROSTATE IN ORENBURG REGION

The article presents the results of the analysis of the federal and regional budget expenditures for drug provision of patients with malignant neoplasms of the prostate gland. There were identify: the structure of costs, the most frequently purchased names of medicines, and the dynamics of the need for preferential medicines in patients with this nosology.The aim of the article to study the structure and dynamics of costs for drug provision, from the regional and federal budgets, patients with malignant neoplasms of the prostate gland (on the example of the Orenburg region).Material and methods. A software package for centralized data processing (provision of necessary drugs, normative reference information, prescription forms for prescriptions for prescriptions of preferential drugs used in the treatment of prostate malignant neoplasms.Results. In the course of the study, it was revealed that in the period from 2017 to 2020, the largest number of drugs used in the treatment of malignant neoplasms of the prostate gland was purchased at the expense of the regional budget of the Orenburg region (4 392 785.86 rubles, 2020). The most frequently purchased drug was Buserelin 3.75 mg No. 1: 2017 (30%), 2018 (40%), 2019 (86%) at the expense of the federal budget. For the period from 2017 to 2020, new anticancer drugs have appeared - "Abiraterone250 mg No. 120" (2017), "Degarelix 80 mg No. 1" and "Enzalutamide 40 mg No. 112" (2020).Conclusions. To improve the quality of provision and availability of pharmaceutical care for urological oncological patients, it is necessary to reduce the financial burden on the regional budget and improve approaches to the formation of an optimal assortment.

prostate cancer, oncology, antineoplastic drugs, preferential provision of the population

1. Каюкова Е. В. Профилактика онкологических заболеваний как одна из главных мультидисциплинарных задач здравоохранения / под ред. Н.В. Ларёвой // VI съезд терапевтов Забайкальского края, 22-23 марта 2018 года, г. Чита [Электронный ресурс]: сборник научных трудов. - Чита. - 2018. - Изд-во: «ЧМГА». - С. 18-21

2. Нигматуллина, Ю.У. [и др.] Анализ потребности в льготных лекарственных препаратах, применяемых для лечения злокачественных новообразований предстательной железы //Известия Самарского научного центра Российской академии наук. - 2015. - Т. 17, №5-2. - С.389-393

3. Нигматуллина Ю.У. [и др.] Маркетинговый анализ ассортимента лекарственных препаратов, применяемых в терапии злокачественных новообразований предстательной железы //Известия Самарского научного центра Российской академии наук. - 2015. - Т.17, №5-2. - С.394-398

4. Постановление Правительства Оренбургской области от 28.06.2019 г. (с изменениями на 28.06.2021 г.) № 451-пп «Об утверждении региональной программы «Борьба с онкологическими заболеваниями». URL: http://publication.pravo.gov.ru/Document/View/5600201907030002 (01.02.2022)